A citation-based method for searching scientific literature

John B Buse, Richard M Bergenstal, Leonard C Glass, Cory R Heilmann, Michelle S Lewis, Anita Y M Kwan, Byron J Hoogwerf, Julio Rosenstock. Ann Intern Med 2011
Times Cited: 389



Silvio E Inzucchi, Richard M Bergenstal, John B Buse, Michaela Diamant, Ele Ferrannini, Michael Nauck, Anne L Peters, Apostolos Tsapas, Richard Wender, David R Matthews. Diabetes Care 2012
Times Cited: 2444




List of shared articles



Times cited

Improving postprandial hyperglycemia in patients with type 2 diabetes already on basal insulin therapy: Review of current strategies.
Guillermo E Umpierrez, Timothy S Bailey, Danielle Carcia, Charles Shaefer, Jay H Shubrook, Neil Skolnik. J Diabetes 2018
8



Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial.
Helena W Rodbard, Ildiko Lingvay, John Reed, Raymond de la Rosa, Ludger Rose, Danny Sugimoto, Eiichi Araki, Pei-Ling Chu, Nelun Wijayasinghe, Paul Norwood. J Clin Endocrinol Metab 2018
92

A practical approach and algorithm for intensifying beyond basal insulin in type 2 diabetes.
Ronald M Goldenberg, Peter Assimakopoulos, Jeremy D Gilbert, Irving S Gottesman, Jean-François Yale. Diabetes Obes Metab 2018
0

Effectiveness of intensification therapies in Danes with Type 2 diabetes who use basal insulin: a population-based study.
R W Thomsen, L M Baggesen, M Søgaard, L Pedersen, H Nørrelund, E S Buhl, C L Haase, S P Johnsen. Diabet Med 2017
4

A global study of the unmet need for glycemic control and predictor factors among patients with type 2 diabetes mellitus who have achieved optimal fasting plasma glucose control on basal insulin.
Denis Raccah, Engels Chou, Stephen Colagiuri, Zsolt Gaàl, Fernando Lavalle, Ashot Mkrtumyan, Elena Nikonova, Nikolaos Tentolouris, Josep Vidal, Melanie Davies. Diabetes Metab Res Rev 2017
21

Exenatide Add-on to Continuous Subcutaneous Insulin Infusion Therapy Reduces Bolus Insulin Doses in Patients with Type 2 Diabetes: A Randomized, Controlled, Open-Label Trial.
Feng-Fei Li, Lanlan Jiang, Liyuan Fu, Hong-Hong Zhu, Peihua Zhou, Danfeng Zhang, Xiao-Fei Su, Jin-Dan Wu, Lei Ye, Jian-Hua Ma. Diabetes Ther 2017
12




Insulin and Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Maria Ida Maiorino, Paolo Chiodini, Giuseppe Bellastella, Annalisa Capuano, Katherine Esposito, Dario Giugliano. Diabetes Care 2017
57


Predictors of response to glucagon-like peptide-1 receptor agonists: a meta-analysis and systematic review of randomized controlled trials.
Matteo Monami, Ilaria Dicembrini, Besmir Nreu, Francesco Andreozzi, Giorgio Sesti, Edoardo Mannucci. Acta Diabetol 2017
17

Patient-reported Outcomes in Patients with Type 2 Diabetes Treated with Dulaglutide Added to Titrated Insulin Glargine (AWARD-9).
Maria Yu, Kate Van Brunt, Zvonko Milicevic, Oralee Varnado, Kristina S Boye. Clin Ther 2017
5